UPDATE: Citigroup Reiterates on Gilead Sciences on Positive Outlook

In a report published Wednesday, Citigroup analyst Yaron Werber reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD ), and raised the price target from $85.00 to $87.00. In the report, Citigroup noted, “Gilead's stock has been posting impressive gains ahead of the much anticipated launch of sofosbuvir for hepC